An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
DRUG

Maralixibat

All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily

Trial Locations (28)

10461

Children's Hospital at Montefiore, The Bronx

15224

Children Hospital of Pittsburgh, Pittsburgh

20007

Medstar Georgetown University Hospital, Washington D.C.

24127

Azienda Ospedaliera Papa Giovanni XXIII - Unita di Pediatria, Bergamo

29425

Medical University of South Carolina, Charleston

31059

CHU de Toulouse - Hôpital des Enfants, Toulouse

32803

Advent Health, Orlando

34010

Koc University Hospital, Istanbul

45229

Cincinnati Children's Hospital, Cincinnati

75390

University of Texas Southwestern Medical Center, Dallas

78229

University of Texas, Health Science Center San Antonio, San Antonio

90027

Children's Hospital Los Angeles, Los Angeles

98105

Seattle Children's Hospital, Seattle

Unknown

Hospital Italiano de Buenos Aires, Buenos Aires

Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde, Vienna

Cliniques Universitaires Saint-Luc, Brussels

Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo

University of Alberta - Women and Children's Health Research Institute, Edmonton

Fundacion Cardioinfantil, Bogotá

Groupement Hospitalier Est Hopital, Femme Mère Enfant de Lyon, Lyon

Medizinische Hochschule, Hanover

Ospedale Pediatrico bambino Gesu', Roma

Hotel Dieu de France, Alfred Naccache, Beirut

Consultario de Joshue David Covarrubias Esquer, Zapopan

Instytut Pomnik Centrum, Zdrowia Dziecka, Warsaw

KK Women's and Children's Hospital, Singapore

Birmingham Children's Hospital, Birmingham

King's College Hospital NHS Foundation Trust, London

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY